cetuximab

(redirected from Erbitux)
Also found in: Medical.

cetuximab

(sɪˈtʌksɪˌmæb)
n
a monoclonal antibody used to treat cancer
References in periodicals archive ?
M2 EQUITYBITES-March 3, 2017-NICE recommends Merck's Erbitux for patients with metastatic colorectal cancer
M2 PHARMA-March 3, 2017-NICE recommends Merck's Erbitux for patients with metastatic colorectal cancer
1% for patients treated,with Erbitux plus FOLFOX,31% decrease in risk of disease progression and 24% decrease in,risk of death was achieved with addition of Erbitux to FOLFOX,First prospective study to evaluate Erbitux in RAS wild-type patients.
In terms of targeted treatments, the metastatic CRC treatment landscape is mature, including the branded treatments Avastin (bevacizumab), Erbitux (cetuximab), and Vectibix (panitumumab), treatments that have extended the survival of metastatic patients compared to chemotherapy-only regimens.
Eli Lilly & Co (Indianapolis IN) and Merck KGaA's (Darmstadt DEU) Erbitux helped a group of cancer patients previously thought to be immune to the treatment in a study that contradicts earlier assumptions of the way the drug works in those with a genetic mutation.
Summary: EoACAo Erbitux plus chemotherapy produces positive results in the difficult to treat triple-negative breast cancer despite not meeting primary endpoint of response rate
The use of Erbitux as a 1st-line treatment for colorectal cancer is an important step in increasing the availability of treatment options for Japanese patients in this setting," said Dr.
We think very highly of ImClone's groundbreaking work in oncology, particularly its success with Erbitux, a blockbuster targeted cancer therapy, and its ability to advance promising biotech molecules in its pipeline," Lilly president and chief executive officer John Lechleiter said in a statement.
ImClone Systems Incorporated (NASDAQ: IMCL), has seen global net sales of Erbitux for the fourth quarter of 2007 increase to $371 million, compared with $293 million in the fourth quarter of 2006, up 27%.
But the disease remains despite courses of gruelling chemotherapy and specialists are now recommending a drug called Erbitux.
Erbitux was approved for use by patients in Scotland last year.
The National Institute for Health and Clinical Excellence has rejected Erbitux for sufferers in England and Wales.